High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 5, 1999, Pages 292-298

  Nademanee, Auayporn ^a   Molina, Arturo ^a   Fung, Henry ^a   Stein, Anthony ^a   Parker, Pablo ^a   Planas, Ina ^a   O'Donnell, Margaret R ^a   Snyder, David S ^a   Kashyap, Ashwin ^a   Spielberger, Ricardo ^a   Bhatia, Ravi ^a   Krishnan, Amrita ^a   Sniecinski, Irena ^a   Vora, Nayana ^a   Slovak, Marilyn ^a   Dagis, Andrew ^a   Niland, Joyce C ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Hodgkin's Disease

Indexed keywords

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REMISSION; RISK FACTOR; SURVIVAL RATE; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0032607282     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(99)70004-2     Document Type: Article

References (26)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992.
2. Viviani S, Bonadonna G, Santaro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P: Alternating versus Hybrid MOPP and ABVD combination in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14:1421, 1996.
3. Connors JM, Klimo P, Adams G, Burns B, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B: Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV Hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 15:1638, 1997.
4. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-crossresistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173, 1990.
5. Wagstaff J, Gregory WM, Swindell R, Crowther D, Lister TA: Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centers. Br J Cancer 58:487, 1988.
6. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ, and members of the Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party: A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 27:624, 1991.
7. Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E, for the Groupe d'Etudes des Lymphomes de l'Adulte: Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer 80:1124, 1997.
8. Prosnit LR, Farber LR, Kapp DS, Scott J, Bertino JR, Fischer JJ, Cadman EC: Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 6:603, 1988.
9. Mendenhall NP, Bennett J, Lynch JW Jr: Is combined modality therapy necessary for advanced Hodgkin's disease? Int J Radiat Oncol Biol Phys 38:583, 1997.
10. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 13:1080, 1995.
11. Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schneider G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Bruntsch C, Tirier C, Müller U, Loeffler M, for the German Hodgkin's Lymphoma Study Group: Moderate dose escalation for advanced-stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 92:4560, 1998.
12. Carella AM, Carlier P, Congiu A, Occhini D, Nati S, Santini G, Pierluigi D, Giordano D, Bacigalupo A, Damasio E: Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 8:99, 1991.
13. Moreau P, Milpied N, Mechinaud-Lacroix F, Mabe B, Rapp MJ, Le Tortorec S, Bourdin S, Dupas B, Haroussean JL: Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leuk Lymphoma 12:51, 1993.
14. Fleury J, Legros M, Columbat P, Cure H, Travade P, Tortochaux J, Dionet C, Chollet P, Linassier C, Lamagnere J-P, Blaise D, Viens P, Maraninchi D, Plagne R: High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma 20:259, 1995.
15. Sureda A, Mataix R, Hernandez-Navarro F, Jarque I, Labuerta JJ, Tomas JF, Brunet S, Caballero D, Conde E, Leon A, Fernandez MN, Lopez A, Maldonado J, Bengoechea E, Callis M, Carrera D, Garcia-Conde J, Garcia-Larana J, Moraleda JM, Morey M, Rifon J, Sieera J, Torres A, Domingo-Albos A: Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transplant 20:283, 1997.
16. Schmitz N, Hasenclever D, Brosteanu O, Carella A, Colambat P, Proctor S, Iegros M, Bradley S, Pearce R, Diehl V, Goldstone AH: Early high-dose therapy to consolidate patients with high-risk Hodgkin's disease in first complete remission? Results of an EBMT/GHSG matched-pair analysis. Blood 86, (Suppl 1): 439a, 1995. [abstr]
17. Moreau P, Fleury J, Brice P, Colombat P, Bouabdallah R, Lioure B, Voillat L, Casanovas O, Francois S, Sadoun A, Lamy T, Lotz JP, Munck JN, Divine M, Ferme C, Peny AM, Fruchart C, Oriol P, Ojeda M, Reman O, Milpied N, Gisselbrecht C, Legros M, Haronsseau JL: Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry. Bone Marrow Transplant 21:787, 1998.
18. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD: Reconstitution of human hematopoietic function with autologous cry-opreserved circulating stem cells. Exp Hematol 14:192, 1986.
19. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker P, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Sniecinski I, Dagis AC, Niland JC, Pezner R, Forman SJ: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 85:1381, 1995.
20. Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, Giordano D, Occhini D, Gatti AM, Bruni R, Spriano M, Nati S, Pierluigi D, Congui M, Vimercati R, Ravette JL, Federico M: Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma 21:63, 1996.
21. Carde P: Who are the high-risk patients with Hodgkin's disease? Leukemia 10:S62, 1996.
22. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease: A prognostic score for advanced Hodgkin's disease. N Engl J Med 339: 1506, 1998.
23. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT Jr: Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol 15:3338, 1997.
24. Horning SJ, Bennett JM, Bartlett NL, Williams J, Neuberg D, Cassileth P: 12 weeks of chemotherapy (Stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin's disease: a limited institution ECOG pilot study. Blood 88 (Suppl 1):673a, 1996. [abstr]
25. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-John U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loffler M, for the German Hodgkin's Lymphoma Study Group: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16:3810, 1998.
26. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535, 1994.